NF-κB p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53-Reference-Cited by-同舟云学术

NF-κB p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53

Published:2017-03-10 Issue:6 Volume:30 Page:854-876
ISSN:0893-3952
Container-title:Modern Pathology
language:en
Short-container-title:Mod Pathol

Author:

Cai Qingqing,Tu Meifeng,Xu-Monette Zijun Y,Sun Ruifang,Manyam Ganiraju C^ORCID,Xu Xiaolu,Tzankov Alexander,Hsi Eric D,Møller Michael B,Medeiros L Jeffrey,Ok Chi Young^ORCID,Young Ken H

Publisher

Springer Science and Business Media LLC

Subject

Pathology and Forensic Medicine

Link

http://www.nature.com/articles/modpathol20175.pdf

Reference47 articles.

1. Chen CD, Sawyers CL . NF-kappaB activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. Mol Cell Biol 2002;22:2862–2870.

2. Basseres DS, Baldwin AS . Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 2006;25:6817–6830.

3. Siebenlist U, Franzoso G, Brown K . Structure, regulation and function of NF-kappaB. Annu Rev Cell Biol 1994;10:405–455.

4. Mathas S, Jöhrens K, Joos S et al. Elevated NF-kappaB p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large-cell, and other peripheral T-cell lymphomas. Blood 2005;106:4287–4293.

5. Staudt LM . Oncogenic activation of NF-kappaB. Cold Spring Harb Perspect Biol 2010;2:a000109.

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of NFKB1 and MyD88 expression levels in a sample of non-Hodgkin lymphoma patients before and during chemotherapy;Egyptian Journal of Basic and Applied Sciences;2024-05-11

2. The Mechanism of Nano-Particles Intervening Invasion and Metastasis of Lymphoma Based on Autophagy Targeted with miR-36b and Orienteering Analysis on Apoptosis Gene;Journal of Biomaterials and Tissue Engineering;2021-11-01

3. SMAD1 as a biomarker and potential therapeutic target in drug-resistant multiple myeloma;Biomarker Research;2021-06-16

4. R-CHOP resistance in diffuse large B-cell lymphoma: biological and molecular mechanisms;Chinese Medical Journal;2020-12-08

5. Targeting CDK12 for Cancer Therapy: Function, Mechanism, and Drug Discovery;Cancer Research;2020-09-21